

PharmaMar initiates first human clinical trial of a new molecule, PM534, for cancer patients

- **This new compound of marine origin is the result of research and development by PharmaMar's R&D team.**

Madrid, December 30th, 2022. - PharmaMar (MSE: PHM) has announced today the initiation of a new Phase I clinical trial with PM534, a novel marine-derived anti-tumor compound resulting from the Company's research program for the treatment of solid tumors.

PM534 has been tested in the laboratory, both in cell cultures (*in vitro*) and in animals (*in vivo*). In both cases, PM534 showed relevant antitumor activity in a wide variety of tumor types, including those with resistance to other chemotherapies.

The objectives of this first human clinical trial are to find the recommended dose and, in turn, to evaluate the safety and efficacy profile.

The trial will be conducted in patients with advanced solid tumors who will be administered the drug intravenously.

Legal warning

This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

About PharmaMar

Headquartered in Madrid, PharmaMar is a biopharmaceutical company, focused on oncology and committed to research and development which takes its inspiration from the sea to discover molecules with antitumor activity. It is a company that seeks innovative products to provide healthcare professionals with new tools to treat cancer. Its commitment to patients and to research has made it one of the world leaders in the discovery of antitumor drugs of marine origin.

PharmaMar has a pipeline of drug candidates and a robust R&D oncology program. It develops and commercializes Yondelis® in Europe and has other clinical-stage programs under development for several types of solid cancers: Zepzelca® and ecubectedin. With subsidiaries in Germany, Italy, France, Switzerland, Belgium, Austria and the United States. PharmaMar wholly owns Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi). To learn more about PharmaMar, please visit us at pharmamar.com

Media Contact:

Lara Vadillo – Communication Director lvadillo@pharmamar.com

Miguel Martínez-Cava – Communication Manager mmartinez-cava@pharmamar.com

Phone: +34 918466000

Capital Markets & Investor Relations:

José Luis Moreno – Capital Markets & Investor Relations Director

Natalia Amo – Capital Markets & Investor Relations

investorrelations@pharmamar.com

Phone: +34 914444500



Or please visit our website at pharmamar.com